Gonadotropin-Releasing Hormone Analogues Reduce the Proliferation of Endometrial Stromal Cells but Not Endometriotic Cells
article
OA: closed
CC0
⤵ 15 in-corpus citations
AI-generated summary
GnRH agonists and antagonists reduced endometrial stromal cell proliferation but not endometriotic stromal cell proliferation, potentially due to lower GnRH receptor expression in endometriotic cells.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
AIMS: We investigated the potential of gonadotropin-releasing hormone (GnRH) agonists and GnRH antagonists to inhibit cell proliferation in endometriotic and endometrial stromal cells. METHODS: Twenty patients with ovarian endometriomas and 18 patients with uterine fibromas were recruited. Endometriotic and endometrial stromal cells were obtained from the ovarian chocolate cyst linings and the eutopic endometria of premenopausal women with uterine fibromas, respectively. RESULTS: GnRH agonist or antagonist treatment attenuated tumor necrosis factor (TNF)-α-induced cell proliferation in the endometrial stromal cells, whereas endometriotic stromal cells did not respond to treatment. The endometriotic stromal cells exhibited a decreased expression of the type I GnRH receptor compared with the endometrial stromal cells. GnRH agonists or antagonists did not repress TNF-α-induced IL-8 production in endometriotic stromal cells. CONCLUSION: GnRH agonists and antagonists have similar effects in slowing the growth of endometrial stromal cells. Endometriotic stromal cells resist the antiproliferative effect of GnRH agonists and antagonists.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (19)
- Comparison of the effects of cetrorelix, a GnRH antagonist, and leuprolide, a GnRH agonist, on experimental endometriosis via openalex
- Drug-induced apoptosis was markedly attenuated in endometriotic stromal cells via openalex
- Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate via openalex
- GnRH II as a possible cytostatic regulator in the development of endometriosis via openalex
- Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis via openalex
- Matrix Metalloproteinases and Endometriosis via openalex
- Pathogenetic Significance of Increased Levels of Interleukin-8 in the Peritoneal Fluid of Patients with Endometriosis via openalex
- Peritoneal fluid-mediated enhancement of eutopic and ectopic endometrial cell proliferation is dependent on tumor necrosis factor-α in women with endometriosis via openalex
- Role of cytokines in endometriosis via openalex
- Serum interleukin-8 levels are elevated in patients with ovarian endometrioma via openalex
- TAK1 activation for cytokine synthesis and proliferation of endometriotic cells via openalex
- Transcriptional Characterizations of Differences between Eutopic and Ectopic Endometrium via openalex
- Tumor Necrosis Factor-α-Induced Interleukin-8 (IL-8) Expression in Endometriotic Stromal Cells, Probably through Nuclear Factor-κB Activation: Gonadotropin-Releasing Hormone Agonist Treatment Reduced IL-8 Expression via openalex
- W2153083446 via openalex
- W2042642675 via openalex
- W2411429076 via openalex
- W2063681422 via openalex
- W1998404051 via openalex
- W2150296078 via openalex
Cited by (15)
- The impact of endometriosis and adenomyosis on the female reproductive system 2022
- Role of inflammation in benign gynecologic disorders: from pathogenesis to novel therapies† 2021
- Role of medical treatment of endometriosis 2021
- Endometriosis diagnosis and medical treatment: Present and future 2021
- A comprehensive review of hormonal and biological therapies for endometriosis: latest developments 2019
- Current and emerging treatment options for endometriosis 2018
- Current and Emerging Therapeutics for the Management of Endometriosis 2018
- Investigational drugs for the treatment of endometriosis, an update on recent developments 2018
- New developments in the medical treatment of endometriosis 2017
- Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics 2016
- The efficiency and safety of using the gonadotropin-releasing hormone agonist Buserelin-long FS in late reproductive-aged patients with endometriosis: A clinical trial 2016
- Differential mRNA expression profiling in ovarian endometriotic tissue with versus without leuprolide acetate treatment 2015
- An overview of early drug development for endometriosis 2015
- Molecular aspects of development and regulation of endometriosis 2014
- Inhibition of dual specificity phosphatase-2 by hypoxia promotes interleukin-8-mediated angiogenesis in endometriosis 2014
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T16:23:13.998983+00:00
- pubmed
- last seen: 2026-05-13T22:15:58.344756+00:00
License: CC0
· commercial use OK